The Maternal Screening Triple Marker test functions as a second-trimester screening test particularly employed in women with elevated risk factors for Down syndrome. The test utilizes α-fetoprotein, human chorionic gonadotropin (hCG), and unconjugated estriol to assess the likelihood of chromosomal abnormalities. Healthcare providers utilize this test as an antenatal screening measure for Down syndrome during the second trimester of pregnancy.